Novo Nordisk A/s

Other

Aventis Pharmaceuticals Inc.

Agouron Pharmaceuticals, Inc.

Aventis Pharmaceuticals Products Inc.

Noro Nordisk A/s

Larry Kenneth Truesdale

Jesper F Lau

Peter Madsen

Carsten Behrens

Anthony Lai Ling

Min Teng

Janos Tibor Kodra

Michael Bruno Plewe

Shenghua Shi

Benoit J Vanasse

James P Sherbine

Michael David Johnson

Ulla Grove Sidelmann

Dan Kiel

Behrend Frederik Lundt

Preben H Olesen

Yufeng Hong

Christian Klarner Sams

Daljit Singh Dhanoa

Anker S Jorgensen

Vlad Edward Gregor

Dilip Ramakant Bhumralkar

Liselotte Bjerre Knudsen

Javier Gonzalez

Atsuo Kuki

Henning Thøgersen

Christine Thomas

Ingrid Petterson

Johannes Cornelis De Jong

Rouvain M Bension

Ranjan Jagath Rajapakse

Henning Th&oslash;gersen

Richard A Bychowski

Tso-sheng Chou

Inge Thøger Christensen

Anker Steen Jøgensen

Christian Sams

Inge Th&oslash;ger Christensen

Josef Vagner

Novel non-peptide GLP-1 agonists, pharmaceutical compositions comprising them, use of the non-peptide GLP-1 agonists for the preparation of pharmaceutical compositions and methods for the treatment and/or prevention of disorders and diseases wherein an activation of the human GLP-1 receptor is beneficial, especially metabolic disorders such as IGT, Type 1 diabetes, Type 2 diabetes and obesity.

Non-peptide GLP-1 agonists

A novel class of compounds, which act to antagonize the action of the glucagon hormone on the glucagon receptor. Owing to their antagonizing effect of the glucagon receptor the compounds may be suitable for the treatment and/or prevention of any glucagon-mediated conditions and diseases such as hyperglycemia, Type 1 diabetes, Type 2 diabetes and obesity.

Glucagon antagonists/inverse agonists

Non-peptide compounds that act as antagonists of the intestinal hormone glucagons-like peptide 1 (GLP-1) have a 9H-b-carboline central motif. The compounds exhibit advantageous physical, chemical and biological properties and inhibit GLP-1 peptide binding to the GLP-1 receptor and/or prevent activation of the receptor by bound GLP-1. The invention further relates to a method of inhibiting the binding of GLP-1 to the GLP-1 receptor and a method of inhibiting the activation of the GLP-1 receptor. Intermediate compounds useful for making non-peptide GLP-1 receptor antagonists are also described.

Non-peptide antagonists of GLP-1 receptor and methods of use

Process for preparing 2,4-dihydroxypyridine and 2,4-dihydroxy-3-nitropyridine

The present invention is directed to a process for preparing 2,4-dihydroxy-pyridine comprising heating a compound of the formula A

Process for preparing 2,4- dihydroxypyridine and 2,4- dihydroxy-3-nitropyridine

A method for forming thin films on substrates. The method includes the steps of forming a self-assembled monolayer film on a substrate where one end of the monolayer bonds to the substrate and the other end forms a surface capable of initiating the formation of a desired film. A preferred method of the invention involves formation of diamond layers over substrates.

Initiation and bonding of diamond and other thin films

Growing community of inventors

San Diego, CA, United States of America

Larry Kenneth Truesdale